• Home
  • News

Sichenzia Ross Ference Carmel LLP represents Calidi Biotherapeutics, Inc. in $4.25 Million Public Offering

calidi therapeutics logo

Press Release – New York, NY – January 14, 2025 Sichenzia Ross Ference Carmel LLP announced that it represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in a public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.

The SRFC team was led by partner Jay Yamamoto and associates Rohini Sud and Chance Moore.